LCZ-696 (Chronic Heart Failure)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Upcoming Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Prognosis 17
3.3 Quality of Life 17
3.4 Symptoms 18
4 Disease Management 20
4.1 Treatment Overview 21
4.1.1 Pharmacological Treatments 23
4.1.2 Mechanical Devices 29
5 Opportunity and Unmet Need 30
5.1 Overview 30
5.2 Lack of Therapies for HF-PEF Patients 31
5.3 Lack of Therapies for Patients with Renal Impairment 32
5.4 Diagnosis of Asymptomatic Left Ventricular Dysfunction 32
5.5 Treatment of Patients with Multiple Comorbidities 33
5.6 Increase in Survival of CHF Patients 33
5.7 Unmet Needs Gap Analysis 34
5.8 Opportunity: Treatment of Patients with HF-PEF 35
5.9 Opportunity: Therapies for Patients with Renal Impairment and Multiple Comorbidities 35
5.10 Opportunity: New Drugs that Show Increase in Survival of CHF Patients 35
6 Pipeline Assessment 36
6.1 Overview 36
6.2 Promising Drugs in Clinical Development 37
7 LCZ-696 38
7.1 Overview 38
7.2 Efficacy 39
7.3 Safety 40
7.4 Dosing and Formulation 40
7.5 Potential Clinical Positioning 40
7.6 Potential Commercial Positioning 41
7.7 Pricing and Reimbursement 41
7.8 SWOT Analysis 42
7.9 Forecast 43
8 Appendix 44
8.1 Bibliography 44
8.2 Abbreviations 46
8.3 Methodology 48
8.4 Forecasting Methodology 48
8.4.1 NYHA Class Segmentation of Total Prevalent CHF Population 48
8.4.2 Diagnosed CHF Population 49
8.4.3 Drug-Treated CHF Population 50
8.4.4 Patient Population Breakdown: HF-REF versus HF-PEF 50
8.4.5 Treatment of HF-REF versus HF-PEF 50
8.4.6 General Pricing Assumptions 51
8.4.7 Generic Erosion 52
8.4.8 Pricing of Pipeline Agents 52
8.5 Physicians and Specialists Included in this Study 53
8.6 Survey of Prescribing Physicians 54
8.7 About the Authors 55
8.7.1 Author 55
8.7.2 Global Head of Healthcare 55
8.8 About GlobalData 56
8.9 Disclaimer 56